CJC-1295 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-20. Numbers and descriptions here follow the published literature rather than marketing material.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
In 1992, Volkman et al. reported the first evidence of dinosterol in a laboratory culture of a marine diatom Navicula sp., indicating that diatoms may be a source of dinosterol in marine sediments. Within this diatom, 4-methyl sterols comprised less than 0.7% abundance, whereas these sterols are much more abundant in dinoflagellates. Notably, the stereochemistry of the C-24 alkyl substituent in the sterols of diatoms is 24α, whereas in dinoflagellates it is 24β. If the C-24 alkylated sterols in Navicula (CS-46c) are the epimers of dinosterol and dinostanol, then this may be used to discriminate between dinoflagellate and diatom sources of "dinosterol" in sediments. However, the C-24 substituents in steroidal compounds rapidly isomerize in sediments such that a mixture of C-23 and C-24 isomers is formed. Therefore, once the sediment reaches a certain thermal maturity, the stereochemistry at the C-24 position can no longer be used to distinguish between diatom and dinoflagellate sources of dinosterol.
For services to Cricket. Richard Broyd, OBE. Philanthropist. For services to Heritage and Conservation. James Alexander Bullion. Lately Executive Director, Adult Social Services, Norfolk County Council and lately President, Association of Directors of Adult Social Services. For services to Social Care. Robert Geoffrey Burrow, MBE. For services to Motor Neurone Disease Awareness. William Morris Bush. Senior Adviser, Premier League. For services to Sport. Dr. Denise Marie Chaffer. Lately Director, Safety and Learning, NHS Resolution and lately President of the Royal College of Nursing. For services to Patient Safety. Dr. Jung Chang. Author. For services to Literature and to History. David George Crozier. Lately Head, Strategic Partnerships and Engagement, Queen's University Belfast. For services to the Economy. Mark Cutifani. Lately Chief Executive, Anglo American. For services to Investment in the Global Mining Industry. Huw Charles Davies. Lately Chief Executive, British Association for Supported Employment. For services to Employment for Disabled People. Mark William Davies. Director, Windsor Framework Taskforce, Cabinet Office. For Public Service. Dr. Laura Miranda Dawson (Laura Gilbert). Director, Data Science, Prime Minister's Office. For services to Technology and Analysis. Richard George Deverell. Director, Royal Botanic Gardens, Kew. For services to Botanical Science and Conservation. Professor Philip John Diamond. Director General, Square Kilometre Array Observatory. For services to Global Radio Astronomy. Catherine Jane Uttley Dovey.
The life science training pathway for clinical scientists follows a similar pathway to that undertaken by medically qualified specialist registrars in pathology. Clinical scientists are therefore the only discipline of non-medical healthcare professionals examined by a Medical Royal College. Clinical scientists who attain both part 1 examination certification and part 2 certification are awarded Fellowship of the Royal College of Pathologists (FRCPath) and are deemed to have the knowledge and expertise expected of a consultant level scientist. Consultant clinical scientist posts generally require candidates to have completed FRCPath qualification to be eligible. All clinical scientists regardless of seniority or specialisation may have other responsibilities including academic appointments, responsibilities as clinical lead for a pathology service, or may have wider hospital responsibilities such as directorship of Infection Prevention and Control, or responsibility for the hospital's Research and Development strategy. Junior clinical scientists may become involved in academic research, working towards a Ph.D. or DClinSci.
Carbodiimides such as dicyclohexylcarbodiimide (DCC) and diisopropylcarbodiimide (DIC) are frequently used for amide bond formation. The reaction proceeds via the formation of a highly reactive O-acylisourea. This reactive intermediate is attacked by the peptide N-terminal amine, forming a peptide bond. Formation of the O-acylisourea proceeds fastest in non-polar solvents such as dichloromethane. DIC is particularly useful for SPPS since as a liquid it is easily dispensed, and the urea byproduct is easily washed away. Conversely, the related carbodiimide 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) is often used for solution-phase peptide couplings as its urea byproduct can be removed by washing during aqueous work-up.
==== Active metabolites ==== A few of the metabolites of oxycodone have also been found to be active as MOR agonists, some of which notably have much higher affinity for (as well as higher efficacy at) the MOR in comparison. Oxymorphone possesses 3- to 5-fold higher affinity for the MOR than does oxycodone, while noroxycodone and noroxymorphone possess one-third of and 3-fold higher affinity for the MOR, respectively, and MOR activation is 5- to 10-fold less with noroxycodone but 2-fold higher with noroxymorphone relative to oxycodone. Noroxycodone, noroxymorphone, and oxymorphone also have longer biological half-lives than oxycodone.
Sources: en.wikipedia.org
== Pharmacology == Dantrolene depresses excitation-contraction coupling in skeletal muscle by acting as a receptor antagonist to the ryanodine receptor, and decreasing free intracellular calcium concentration.
The other route uses glutathione (GSH) to conjugate with arsenic (III) to form an arsenic (GS) 3 complex. This complex can form a monomethylated arsenic (III) GS complex, using Cyt19 arsenic methyltransferase, and this monomethylated GS complex is in equilibrium with the monomethylated arsenic (III). Cyt19 arsenic methyltransferase can methylate the complex one more time, and this forms a dimethylated arsenic GS complex, which is in equilibrium with a dimethyl arsenic (III) complex. Both of the mono-methylated and di-methylated arsenic compounds can readily be excreted in urine. However, the monomethylated compound was shown to be more reactive and more toxic than the inorganic arsenic compounds to human hepatocytes (liver), keratinocytes in the skin, and bronchial epithelial cells (lungs). Studies in experimental animals and humans show that both inorganic arsenic and methylated metabolites cross the placenta to the fetus, however, there is evidence that methylation is increased during pregnancy and that it could be highly protective for the developing organism. Enzymatic methylation of arsenic is a detoxification process; it can be methylated to methylarsenite, dimethylarsenite or trimethylarsenite, all of which are trivalent. The methylation is catalyzed by arsenic methyltransferase (AS3MT) in mammals, which transfers a methyl group on the cofactor S-adenomethionine (SAM) to arsenic (III). An orthologue of AS3MT is found in bacteria and is called CmArsM. This enzyme was tested in three states (ligand free, arsenic (III) bound and SAM bound).
== Further reading == Robert Kempa, Plebiscyt 1920 r. w północno-wschodniej części Mazur (na przykładzie powiatu giżyckiego). In Masovia. Pismo poświęcone dziejom Mazur, 4/2001, Giżycko 2001, pp. 149–157 (in Polish) Andreas Kossert, Ostpreussen: Geschichte und Mythos, ISBN 3-88680-808-4 (in German) Andreas Kossert, Religion versus Ethnicity: A Case Study of Nationalism or How Masuria Became a "Borderland", in: Madeleine Hurd (ed.): Borderland Identities: Territory and Belonging in Central, North and East Europe. Eslöv 2006, S. 313–330 Adam Szymanowicz, Udział Oddziału II Sztabu Generalnego Ministerstwa Spraw Wojskowych w pracach plebiscytowych na Warmii, Mazurach i Powiślu w 1920 roku. In Komunikaty Mazursko – Warmińskie, 4/2004, pp. 515–530.(in Polish) Wojciech Wrzesiñsk, Das Recht zur Selbstbestimmung oder der Kampf um staatliche Souveränität – Plebiszit in Ostpreußen 1920 in AHF Informationen Nr. 54 vom 20.09.2000 [2] (in German)
In 2024, the government looked into legalising these services.Bus services operate more than 700 routes across the territory, with smaller public light buses (also known as minibuses) serving areas standard buses do not reach as frequently or directly. Expressways and truck roads, organised with the Hong Kong Strategic Route and Exit Number System, connect all major areas of the territory. The Hong Kong–Zhuhai–Macau Bridge provides a direct route to the western side of the Pearl River estuary.
==== Monoamine reuptake inhibition ==== Bromantane was once thought to act as a reuptake inhibitor of serotonin and dopamine. While bromantane can inhibit the reuptake of serotonin, dopamine, and to a lesser extent norepinephrine in vitro in rat brain tissue, the concentrations required to do so are extremely high (50–500 μM) and likely not clinically relevant. Although one study found an IC50 for dopamine transport of 3.56 μM, relative to 28.66 nM for mesocarb; neither drug affected serotonin transport at the tested concentrations, in contrast. The lack of typical stimulant-like effects and adverse effects seen with bromantane may help corroborate the notion that it is not acting significantly as a monoamine reuptake inhibitor, but rather via a different mechanism.
Sources: en.wikipedia.org
It also possible that the cells involved in these pathological states favor the reversed action of 5-HEDH, conversion of 5-oxo-ETE to 5(S)-HETE, as a consequence of reductions in oxidative stress and thereby NADP+/NADPH ratios; such cells might then actually "detoxify" 5-oxo-ETE and contribute to resolving the pathological states.
Enriched uranium was first manufactured in the early 1940s when the United States and the United Kingdom began their nuclear weapons programs. Later in the decade, France and the Soviet Union began their nuclear weapons and nuclear power programs. Depleted uranium was originally stored as an unusable waste product (uranium hexafluoride) in the hope that improved enrichment processes could extract additional quantities of the fissionable 235U isotope. This re-enrichment recovery of the residual uranium-235 is now in practice in some parts of the world; e.g. in 1996 over 6,000 tonnes (6,600 short tons) were upgraded in a Russian plant. In the 1970s, the Pentagon reported that the Soviet military had developed armor plating for Warsaw Pact tanks that NATO ammunition could not penetrate. The Pentagon began searching for materials to make denser armor-piercing projectiles. After testing various metals, ordnance researchers settled on depleted uranium. The US and NATO militaries used DU penetrator rounds in the 1991 Gulf War, the Bosnia war, bombing of Serbia, the 2003 invasion of Iraq, and 2015 airstrikes on ISIS in Syria. It is estimated that between 315 and 350 short tons (286 and 318 t) of DU were used in the 1991 Gulf War.
== Effect of molecular weight == At constant pressure and temperature, the root-mean-square speed and therefore the effusion rate are inversely proportional to the square root of the molecular weight. Gases with a lower molecular weight effuse more rapidly than gases with a higher molecular weight, so that the number of lighter molecules passing through the hole per unit time is greater.
== Safety == Kojic acid may be weakly carcinogenic, according to some animal studies. It is not believed to reach carcinogenic thresholds in human skin, and is demonstrably safe at the level used in cosmetics. In the European Union, the cosmetic use of kojic acid is restricted. Under Commission Regulation (EU) 2024/996, it was added to Annex III of the Cosmetics Regulation (EC) No 1223/2009, permitting it only in face and hand products at a maximum concentration of 1%. The limit applies to products placed on the EU market from 1 November 2025.
Gastrointestinal cancer may occur at any point in the gastrointestinal tract, and includes mouth cancer, tongue cancer, oesophageal cancer, stomach cancer, and colorectal cancer. One possible factor in the etiology of gastrointestinal cancers is excessive exposure of the digestive organs to bile acids. Inflammatory conditions. Ileitis is an inflammation of the ileum, colitis is an inflammation of the large intestine. Intestinal necrotizing arteriolitis is an inflammation of the arteries in the intestines, causing widespread severe acute lesions. Appendicitis is inflammation of the appendix located at the caecum. This is a potentially fatal condition if left untreated; most cases of appendicitis require surgical intervention. Diverticular disease is a condition that is very common in older people in industrialized countries. It usually affects the large intestine but has been known to affect the small intestine as well. Diverticulosis occurs when pouches form on the intestinal wall. Once the pouches become inflamed it is known as diverticulitis. Inflammatory bowel disease is an inflammatory condition affecting the bowel walls, and includes the subtypes Crohn's disease and ulcerative colitis. While Crohn's can affect the entire gastrointestinal tract, ulcerative colitis is limited to the large intestine. Crohn's disease is widely regarded as an autoimmune disease. Although ulcerative colitis is often treated as though it were an autoimmune disease, there is no consensus that it actually is such.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.